50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:CODX

Co-Diagnostics - CODX Stock Forecast, Price & News

$3.02
+0.15 (+5.23%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.76
$3.03
50-Day Range
$2.87
$7.01
52-Week Range
$2.76
$10.90
Volume
388,703 shs
Average Volume
421,014 shs
Market Capitalization
$102.02 million
P/E Ratio
3.39
Dividend Yield
N/A
Price Target
$7.00

Co-Diagnostics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
131.8% Upside
$7.00 Price Target
Short Interest
Bearish
6.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.10
Upright™ Environmental Score
News Sentiment
0.42mentions of Co-Diagnostics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
200.00%
From $0.09 to $0.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

140th out of 1,080 stocks

Surgical & Medical Instruments Industry

13th out of 104 stocks

CODX stock logo

About Co-Diagnostics (NASDAQ:CODX) Stock

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CODX Stock News Headlines

See More Headlines
Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CODX Company Calendar

Last Earnings
8/11/2022
Today
9/24/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+131.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$36.66 million
Pretax Margin
42.82%

Debt

Sales & Book Value

Annual Sales
$97.89 million
Cash Flow
$1.35 per share
Book Value
$4.65 per share

Miscellaneous

Free Float
33,376,000
Market Cap
$102.02 million
Optionable
Not Optionable
Beta
-1.30

Key Executives

  • Mr. Dwight H. Egan (Age 69)
    Chairman, CEO & Pres
    Comp: $1.02M
  • Mr. Brian L. Brown CPA (Age 46)
    CFO & Company Sec.
    Comp: $730.62k
  • Mr. Reed L. Benson (Age 74)
    Gen. Counsel
    Comp: $385.85k
  • Dr. Brent C. Satterfield Ph.D. (Age 45)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Jesse Montgomery
    Chief Scientific Officer
  • Mr. Andrew Benson
    Head of Investor Relations
  • Dr. Mayuranki Almaula
    Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry
    Head of Commercialization LATAM/EUR













CODX Stock - Frequently Asked Questions

Should I buy or sell Co-Diagnostics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CODX shares.
View CODX analyst ratings
or view top-rated stocks.

What is Co-Diagnostics' stock price forecast for 2022?

4 Wall Street research analysts have issued 12-month price targets for Co-Diagnostics' shares. Their CODX share price forecasts range from $5.00 to $9.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 131.8% from the stock's current price.
View analysts price targets for CODX
or view top-rated stocks among Wall Street analysts.

How have CODX shares performed in 2022?

Co-Diagnostics' stock was trading at $8.93 at the beginning of the year. Since then, CODX stock has decreased by 66.2% and is now trading at $3.02.
View the best growth stocks for 2022 here
.

When is Co-Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our CODX earnings forecast
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) issued its earnings results on Thursday, August, 11th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.15 by $0.25. The firm had revenue of $5.02 million for the quarter, compared to analysts' expectations of $20.50 million. Co-Diagnostics had a trailing twelve-month return on equity of 18.62% and a net margin of 35.80%.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.02%), Millennium Management LLC (0.49%), Advisor Resource Council (0.19%), Bank of Montreal Can (0.18%), Cubist Systematic Strategies LLC (0.16%) and Northern Trust Corp (0.15%). Insiders that own company stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends
.

How do I buy shares of Co-Diagnostics?

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $3.02.

How much money does Co-Diagnostics make?

Co-Diagnostics (NASDAQ:CODX) has a market capitalization of $102.02 million and generates $97.89 million in revenue each year. The company earns $36.66 million in net income (profit) each year or $0.89 on an earnings per share basis.

How many employees does Co-Diagnostics have?

The company employs 101 workers across the globe.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The official website for the company is www.codiagnostics.com. The company can be reached via phone at (801) 438-1036 or via email at investors@codiagnostics.com.

This page (NASDAQ:CODX) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.